Bayer AG is “really doubling down on expanding our presence in the United States,” president of pharmaceuticals for the Americas region Sebastian Guth said in an interview with Scrip, with a commitment to spend $1bn on research and development in the US in 2023. The investment is meant to capitalize on scientific advancements and to back Bayer’s increasing commercial focus on the US, where the company will generate a greater percentage of its revenue going forward.
“Historically, our revenue contribution out of the United States is simply smaller than it would be for a typical pharmaceutical company of our size,” Guth said. “We reported revenues in 2022 of $4.7bn in North America … and that's essentially less than 25% of our overall revenue in pharmaceuticals … and we see an opportunity to significantly increase our commercial presence and the revenue contribution out of the US over this decade
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?